Appendix 4C - Quarterly
Released
Latest announcements
Announcement summary
Appendix 4C - Quarterly
The latest 4C report from Emyria highlights our collaborations with leading organisations & the beginning of recruitment for our Phase 3 clinical trial of EMD-RX5 - which has already come to fruition with January's dosing announcement!
Ask a question
Your question will be sent privately to Emyria. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Emyria a question about this announcement.